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Abstract
Osteoarthritis (OA) is a common complex disease with high public health burden and no curative therapy. High bone mineral
density (BMD) is associated with an increased risk of developing OA, suggesting a shared underlying biology. Here, we
performed the first systematic overlap analysis of OA and BMD on a genome wide scale. We used summary statistics from
the GEFOS consortium for lumbar spine (n¼31,800) and femoral neck (n¼32,961) BMD, and from the arcOGEN consortium for
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three OA phenotypes (hip, ncases¼3,498; knee, ncases¼3,266; hip and/or knee, ncases¼7,410; ncontrols¼11,009). Performing LD
score regression we found a significant genetic correlation between the combined OA phenotype (hip and/or knee) and
lumbar spine BMD (rg¼0.18, P¼2.23102), which may be driven by the presence of spinal osteophytes. We identified 143
variants with evidence for cross-phenotype association which we took forward for replication in independent large-scale OA
datasets, and subsequent meta-analysis with arcOGEN for a total sample size of up to 23,425 cases and 236,814 controls.
We found robustly replicating evidence for association with OA at rs12901071 (OR 1.08 95% CI 1.05–1.11, Pmeta¼3.121010),
an intronic variant in the SMAD3 gene, which is known to play a role in bone remodeling and cartilage maintenance. We
were able to confirm expression of SMAD3 in intact and degraded cartilage of the knee and hip. Our findings provide the first
systematic evaluation of pleiotropy between OA and BMD, highlight genes with biological relevance to both traits, and estab-
lish a robust new OA genetic risk locus at SMAD3.
Introduction
Osteoarthritis (OA) is a degenerative disease of the joints affect-
ing over 40% of people over 70 years (1). Hallmarks of OA include
cartilage degradation, joint-space narrowing, formation of os-
teophytes within the joint and subchondral bone remodeling
(2,3). Due to a lack of therapeutic options, the main treatment
strategy consists of pain management and, in severe cases, joint
replacement surgery (2). OA is a complex disorder with the 18
currently known risk loci accounting for approximately 11% of
disease heritability (4). The biggest OA genome-wide association
study (GWAS) published to date was conducted by the arcOGEN
consortium in a two-stage design, culminating in a total discov-
ery sample of 7,410 cases and 11,009 controls (5,6). Cases in the
arcOGEN study had radiographic hip or knee OA (defined as a
Kellgren Lawrence score 2), and approximately 80% had un-
dergone total joint replacement surgery, indicating disease pro-
gression to a severe degree (6).
In addition to establishing bigger OA sample collections,
studying OA in the context of related phenotypes may add to
the currently short list of established loci. While most GWAS to
date have investigated a single phenotype, it is estimated that
around 5% of risk variants and 16% of genes identified through
these studies have pleiotropic effects on multiple phenotypes
(7). In recent years, the accumulation of large-scale genomic
datasets has made it possible to study genetic pleiotropy by in-
corporating data from multiple epidemiologically linked traits.
Leveraging available summary data of correlated traits to iden-
tify common genetic risk factors can help pinpoint causal path-
ways and refine our understanding of disease mechanisms.
OA in itself is a heterogeneous disorder, with heritability vary-
ing depending on the affected joint. Of the 18 published risk loci
to date, 6 and 7 are associated with knee OA only and hip OA
only, respectively, while 5 are associated with both hip and
knee OA (4). This further highlights how phenotypic variation is
reflected by genetics, and demonstrates the need for strict phe-
notype definitions.
The link between bone mineral density (BMD) and OA was
first reported in 1972 by Foss and Byers, who observed higher
BMD in femoral heads excised during OA-related hip replace-
ment surgery (8). Since then, a number of cross-sectional and
longitudinal studies have found higher femoral neck (FN) and
lumbar spine (LS) BMD, as well as total body BMD to be associated
with incident OA at the hip, knee and other joint sites (9–12).
Findings with regards to the relationship between BMD and
OA progression are less clear (13). Elevated bone turnover – usu-
ally a marker for decreased BMD – was reported in patients with
progressive knee OA compared to patients with stable OA (14).
Decreased baseline femoral neck BMD (FNBMD) has also been
associated with knee OA progression (15,16). Conversely, data
from the Rotterdam study showed a non-significant trend of
higher odds of knee OA progression with increased lumbar
spine BMD (LSBMD) (17), while another study found no link be-
tween knee OA progression and total body- or FNBMD (9).
The largest genetic studies on BMD to date have been carried
out by the Genetic Factors for Osteoporosis (GEFOS) consortium:
a large-scale GWAS in 2012 found 56 loci associated with BMD
(18); more recently, a rare variant of large effect was identified
combining whole-genome sequencing and GWAS imputation
(19). Several biological mechanisms are implicated in both OA
and BMD, such as bone remodeling, mesenchymal stem cell dif-
ferentiation and inflammation (2,6,18,20). RUNX2, a key tran-
scription factor regulating endochondral ossification and
osteoblast differentiation (21,22), has been associated with both
OA and BMD based on its proximity to genome-wide significant
variants (6,18). The other locus with known GWAS hits for both
traits is KLHL42 (or KLHDC5), although its biological relevance re-
mains unclear (6,18).
In addition, Yerges-Armstrong and colleagues have previ-
ously shown nominal association of four BMD-linked single nu-
cleotide polymorphisms (SNPs) with knee OA (23). However,
despite the long-established epidemiologic link and shared biol-
ogy, the genetic overlap of OA and BMD has not yet been as-
sessed on a genome-wide level. Here, we present results from
the first genome-wide analysis establishing shared genetic aeti-
ology between OA and BMD.
Results
Known OA risk loci in BMD
Six loci associated with OA were nominally significant for FN-
or LSBMD, including the SUPTH3/CDC5L locus, which is close to
RUNX2, and KLHL42/PTHLH (Supplementary Material, Table S1).
Genome-wide correlation
We used linkage disequilibrium (LD) score regression to get an es-
timate of the genome-wide genetic correlation between OA and
BMD. There was a significant correlation between combined OA
and LSBMD (correlation¼ 0.18; P¼ 0.022), but not hip or knee OA
and LSBMD or between FNBMD and any OA phenotype (Fig. 1).
Extent of shared association signals
We found evidence for significant overlap of association signals
at different P-value thresholds (Pt) between all three OA catego-
ries and LSBMD (permutation adjusted P-value (Pperm)<0.05)
(Table 1).
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Analysis of the combined OA and LSBMD data resulted in sig-
nificant overlap P-values at Pt¼0.001 and 0.005, as well as at less
stringent Pt. Four SNPs overlap at Pt¼5104 (rs17158899,
rs4536164, rs11826287 and rs630765), one of which (rs11826287) is
genome-wide significantly associated with FNBMD (P¼ 3.611014)
and maps to an intron in LRP5.
The highest overlap was observed between hip OA and
LSBMD, with six SNPs overlapping at Pt¼5104 (Pperm¼5.7105).
Two of these SNPs are genome-wide significantly associated with
BMD in GEFOS (rs1524928, P¼ 5.29109 and rs716255,
P¼ 2.071011). A significant overlap was also observed for Pt of
0.001, 0.005 and 0.01 in the hip OA-LSBMD comparison.
Compared to the hip OA and LSBMD analysis, overlap P-val-
ues for the knee OA and LSBMD comparison were at least one
order of magnitude smaller. Four SNPs (rs7104420, rs9466056,
rs881803 and rs4536164) overlapped at Pt¼5104 in this analy-
sis (Pperm¼4.21103). Two of these, rs4536164 and rs9466056,
fall within known BMD risk loci (18).
Overlap signal was much weaker for the OA and FNBMD com-
parisons, with only five Pt reaching statistical significance
(Pt¼ 0.001 for knee OA, Pt¼ 0.005 and 0.01 for hip OA, and Pt¼ 0.001
and Pt¼ 0.005 for combined OA). The SNP overlapping at Pt¼5104
for hip OA and FNBMD (rs1524928) was also among the six SNPs
identified in the hip OA and LSBMD analysis. Two SNPs overlapped
at this Pt for knee OA, one being rs9466056 and the other rs1283614,
which maps to an intron of the BMD locus MEF2C (24).
Evidence for colocalising regions
We employed a regional Bayesian colocalisation test that mea-
sures the posterior probabilities (PP) for each of four alternative
hypotheses compared to one global null hypothesis (i.e. no asso-
ciations in that region). We identified four independent genomic
regions with a high posterior probability (PP) of harbouring one
causal variant common to both traits analysed (PP for hypothe-
sis 3 0.9) (Table 2). The region containing the RPS6KA5 gene
was identified by three comparisons (combined OA and LSBMD,
hip OA and LSBMD, and hip OA and FNBMD). The most strongly
associated SNPs in this region have genome-wide significant as-
sociations with increased BMD at both the LS and FN (rs1286147
and rs1286063, P< 5108) and nominally significant associa-
tions with increased risk of combined and hip OA (rs1286077,
P< 0.05); the three SNPs are in perfect LD (r2¼1.00 for each pair-
wise combination).
Two further regions were identified in the hip OA and
LSBMD analysis; one of these spans a known BMD locus close to
the KCNMA1 gene, while the other does not contain genome-
wide significant variants for either OA or BMD.
Figure 1. Genetic correlation between osteoarthritis (OA) and bone mineral density (BMD) as estimated by LD score regression. Rectangles show the correlation esti-
mate (middle horizontal line) and standard errors (upper and lower bounds) of each comparison. Rectangles are coloured according to the strength of correlation.
Significant correlation estimates are marked by an asterisk. LSBMD¼ lumbar spine BMD; FNBMD¼ femoral neck BMD.
Table 1. SNP-based overlap analysis of OA and BMD. For each comparison, the total number of SNPs present in both datasets after LD-pruning
is given, as well as the number of SNPs falling below each P-value threshold (Pt). Pperm¼ empirical overlap p-value obtained through permuta-
tion analysis
Combined OA Hip OA Knee OA
LSBMD FNBMD LSBMD FNBMD LSBMD FNBMD
Total number of SNPs 75,015 75,161 74,999 75,147 75,125 75,270
Pt SNPs P_perm SNPs P_perm SNPs P_perm SNPs P_perm SNPs P_perm SNPs P_perm
0.5 28,940 8.53 102 27,599 2.74 101 28,563 1.64 101 27065 7.33 101 28,910 7.95 101 27,534 5.84 102
0.1 2,633 7.92 102 2,119 5.41 101 2,513 1.46 102 2057 1.74 101 2,620 3.67 102 2,131 2.33 101
0.05 931 1.25 102 698 2.35 101 868 1.42 102 647 2.47 101 939 8.98 104 700 3.10 102
0.04 682 2.41 103 486 2.33 101 641 6.48 104 434 4.99 101 680 4.74 104 474 1.27 101
0.03 451 1.20 103 314 6.57 102 416 1.02 103 272 4.20 101 437 2.87 103 291 3.27 101
0.02 251 1.95 103 160 1.07 101 239 6.10 105 150 6.31 102 244 1.59 103 152 3.03 101
0.01 87 2.79 102 60 5.84 102 87 2.97 104 52 4.94 102 88 3.01 103 53 2.18 101
0.005 37 6.89 103 24 2.43 102 38 3.04 104 26 6.39 104 29 1.97 101 16 6.94 101
0.001 10 3.90 105 3 4.52 102 7 1.68 103 1 1.00 6 1.12 102 4 3.39 102
5 104 4 6.81 103 0 1.00 6 5.70 105 1 5.64 102 4 4.21 103 2 7.12 102
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The region identified in the knee OA and FNBMD analysis
contains one lead SNP for both traits, rs9466056, which is a
known variant associated with high FN and LSBMD mapping to
an intergenic region between CDKAL1 and SOX4.
We also identified three regions (Table 2) with a high PP of
harbouring two distinct causal variants (PP for hypothesis
4 0.9). All three of these contain a known BMD locus, with the
top SNPs for LSBMD mapping to introns of IDUA, CCDC170 and
PDXDC1. The top SNPs for knee and hip OA are nominally asso-
ciated (P< 0.05) with these respective phenotypes in arcOGEN.
Gene and pathway analysis
Of the individual genes significantly associated (Q< 0.05) with
at least one OA or BMD phenotype, SUPTH3, COL11A1, and
APCDD1 overlapped between OA and BMD (Supplementary
Material, Table S2). All three include variants that were identi-
fied in the SNP-wise overlap analysis and taken forward for
replication.
There were no pathways significantly associated with any
OA phenotype in any of the analyses. One of the CP pathways
was associated with FNBMD (“basal cell carcinoma”, Q¼ 0.02)
when allowing a 20 kilobase (kb) window around genes. Using
GO annotations, a total of 33 unique pathways were associated
with either BMD phenotype using strict or lenient gene defini-
tions (Supplementary Material, Tables S3–S5), including several
with direct biological relevance, such as “regulation of ossifica-
tion” or “osteoblast development”.
Cross-phenotype meta-analysis
To search for potential novel associations not identified by
single-trait GWAS, we performed a cross-phenotype meta-anal-
ysis between each pairwise combination of OA and BMD data-
sets. Using the CPASSOC method (25), we computed two
statistics, Shom and Shet, which assume homogeneous and het-
erogeneous effects across studies, respectively. The quantile–
quantile and Manhattan plots of these analyses are shown in
Supplementary Material, Figures S1–S4. We identified 13 inde-
pendent associations not previously reported for BMD or OA,
which we followed up in the UK Biobank combined OA dataset
(Supplementary Material, Table S10). One SNP, rs11164649, was
nominally significant (P< 0.05). This SNP lies in an intron of the
COL11A1 gene and is in strong LD (r2¼0.92) with a variant
(rs1903787) identified in the SNP-wise overlap analysis which
was taken forward for replication.
Replication and meta-analysis for OA
We meta-analysed 143 SNPs identified in the colocalisation
and/or P-value based overlap analysis in arcOGEN, UK Biobank
and deCODE (Supplementary Material, Table S6). None of the
SNPs taken forward are genome-wide significantly associated
with arcOGEN. We found a significant excess of independent
SNPs with the same direction of effect in all three meta-analysis
cohorts among variants with Pmeta<0.05 (binomial sign test
P¼ 7.751011), as well as all independent SNPs included in the
meta-analysis (binomial sign test P¼ 0.03).
Variants within several genes linked to bone, cartilage and
extracellular matrix biology, including APCDD1, SUPTH3,
COL11A1, NOTCH4, SEMA3A, LGR4, PTCH1 and RPS6KA5, were as-
sociated at Pmeta<0.05 (Supplementary Material, Table S6).
Two variants reached genome-wide significance in the
meta-analysis across arcOGEN, deCODE and UK Biobank:
rs12901071 (OR 1.08 95% CI 1.05–1.11, Pmeta¼3.121010) and
rs10518707 (OR 1.07, 96% CI 1.03–1.09, Pmeta¼2.15108). Both
are intronic variants in the SMAD3 gene (r2¼0.645) and were
identified in the SNP-wise overlap analysis of combined OA vs.
LSBMD and hip OA vs. LSBMD, respectively.
Both new genome-wide significant SNPs for OA were im-
puted in the arcOGEN data (imputation info score> 0.95) and
are nominally associated with combined OA (Supplementary
Material, Table S6; Fig. S2). They are also nominally associated
with increased LSBMD in GEFOS (rs12901071, P¼ 1.58103 and
rs10518707, P¼ 3.47105) (Fig. 2), but not FNBMD (rs12901071,
P¼ 3.72101 and rs10518707, P¼ 2.46101). SMAD3 is associ-
ated (P< 0.05) with LS and FNBMD, hip and combined OA in the
gene analysis (Supplementary Material, Table S7), although this
association only holds for LSBMD after using false discovery
rate (FDR) correction (Q¼ 6.92106).
In the colocalisation analysis, the region in which both top
SNPs reside (chr15:67,095,629-69,017,421) has a PP of containing
a single pleiotropic variant associated with hip OA and LSBMD
(hypothesis 3) of 0.88.
Functional follow-up of SMAD3
Using RNA sequencing data, we confirmed the expression of
SMAD3 in low-grade degenerate articular cartilage of 12 knee
and 9 hip OA patients undergoing total joint replacement (26)
(Supplementary Material, Fig. S5). SMAD3 is among the 30%
most expressed genes in the knee articular cartilage samples,
and among the 15% most expressed genes in the hip articular
cartilage samples.
Table 2. Regions with strong evidence of pleiotropy. For each region the number of SNPs, start and stop position in basepairs (bp) and most
strongly associated SNPs for OA and BMD are given. Chromosome coordinates are in hg19. Hypothesis 3¼one causal variant; hypothesis
4¼ two distinct causal variants; PP¼posterior probability
Analysis SNPs Chr Start (bp) Stop (bp) Top SNP BMD Top SNP OA PP
Hypothesis 3 combinedOA and LSBMD 817 chr14 91297823 93129850 rs1286147; rs1286063 rs1286077 0.95
hipOA and FNBMD 817 chr14 91297823 93129850 rs1286147 rs1286077 0.98
hipOA and LSBMD 817 chr14 91297823 93129850 rs1286147; rs1286063 rs1286077 0.99
hipOA and LSBMD 1242 chr10 78708452 80875213 rs7071206 rs716255 0.92
hipOA and LSBMD 531 chr1 44974119 46897698 rs7554123 rs7545984 0.91
kneeOA and FNBMD 1235 chr6 19208477 21677746 rs9466056 rs9466056 0.99
Hypothesis 4 hipOA and LSBMD 268 chr4 696848 1415698 rs3755955 rs3755920 0.97
kneeOA and LSBMD 382 chr16 14464538 16152940 rs4985155 rs9935327 0.95
kneeOA and LSBMD 1070 chr6 150255029 151910904 rs4869742 rs9384514 0.90
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Discussion
The analysis of shared genetic aetiology across epidemiologi-
cally linked traits can enhance power to identify disease
variants and shed light into the biological mechanisms under-
pinning these associations. We conducted the first genome-
wide overlap analysis of BMD and OA using summary statistics
from the two largest GWAS of these two traits.
We identified 143 variants with evidence for association
with OA and BMD. Many of these reside in or near biologically
relevant genes, two of which (KLHL42/KLHDC5 and SUPT3H/
RUNX2) are established loci for both traits (6,18). Variants in
three loci (SUPTH3, APCDD1, and COL11A1) were also signifi-
cantly associated with at least one OA and BMD phenotype in
the gene analysis. APCDD1 is an inhibitor of WNT signaling (27),
which is implicated in both OA and BMD. COL11A1 encodes col-
lagen type 11, an important component of cartilage and bone,
and has been associated with OA in a candidate gene meta-
analysis (28). Other examples include the LGR4 gene, in which a
rare variant in the Icelandic population has been associated
with low BMD and osteoporotic fractures (29); and SEMA3A,
which affects bone remodeling in rats (30).
We identified novel genome-wide significant associations at
two intronic SNPs in SMAD3, and confirm expression of this gene
in primary chondrocytes from articular cartilage of OA patients
undergoing total joint replacement surgery. Activated SMAD3
acts downstream of TGF-b, repressing osteoblast differentiation
and the production of bone matrix (31,32). It also represses the
cartilage-degrading enzyme matrix metalloproteinase 13 in
chondrocytes (32). Missense mutations in a conserved protein
domain of SMAD3 have been linked to aneurysm-osteoarthritis
syndrome, a congenital disorder characterised by arterial aneu-
rysms, heart abnormalities and early-onset OA (33).
Due to its role in bone and cartilage biology, SMAD3 has been
previously assessed in a candidate gene study of hip and knee
OA (34). Despite their small sample size (number of cases< 400),
the investigators found nominal associations (P< 0.05) for both
OA phenotypes in their discovery, which were further
strengthened in a meta-analysis (hip OA P¼ 4104; knee OA
P¼ 7.5106). Notably, their top signal (rs12901499) maps to the
same locus as our lead SNP (r2¼0.645).
More recently, two studies have shown SMAD3 expression to
be correlated with the genotype at a 3’UTR SNP (35), and to be
significantly higher in cartilage from OA patients compared to
healthy controls (36). The authors postulate that this could be a
compensatory mechanism to counteract existing cartilage dam-
age, or that SMAD3 expression levels outside a narrow range
have detrimental effects.
We observed a stronger overlap between LSBMD and OA.
The fact that only the correlation between combined OA and
LSBMD was significant could be due to the bigger sample size in
this OA dataset compared to the hip or knee OA data. While the
FN- and LSBMD datasets are very similar in size, the knee OA
and hip OA datasets each contain approximately half the num-
ber of cases compared to the combined OA dataset. This differ-
ence in power might at least partly explain why the genetic
correlation estimates for joint-specific OA and LSBMD did not
achieve statistical significance. Epidemiological data from the
Chingford study have shown increased baseline BMD to be asso-
ciated with incident radiographic knee OA, with the mean in-
crease in LSBMD being approximately twice as high as the
increase in FNBMD (10,15). Incident knee OA was also linked to
higher baseline LSBMD, but not FNBMD, in the Baltimore
Longitudinal Study of Ageing (37). The reasons for this differen-
tial association of FN- and LSBMD with OA remain unclear. One
possible explanation could be the comorbidity of knee and spi-
nal OA, characterised by spinal osteophytes, which could lead
to increased LSBMD measurements. However, in one study, ad-
justment for the presence of osteophytes at the lumbar spine
did not change the strength of association between OA and
LSBMD (10). Damage to the spine accumulates over time and
can lead to changes such as breakdown of the invertebral discs,
scoliosis and osteochondrosis. This process is also referred to as
degenerative disc disease (DDD). Although the association be-
tween DDD and LSBMD remains inconclusive (38–41), it is
known that the presence of degenerative features can increase
LSBMD measurements obtained via dual X-ray absorptiometry
(42). While this may have contributed to the observed associa-
tion between LSBMD and OA, we found genetic correlations of a
similar magnitude between OA and skull, as well as total body
BMD measurements in a paediatric cohort (43) (Supplementary
Material, Table S11; Supplementary Methods). As DDD and re-
lated features such as osteophytes are unlikely to be present in
young individuals, these results suggest that the correlation be-
tween OA and LSBMD is not purely artefactual.
Our analyses showed a greater degree of overlap between
hip OA and both BMD measurements than between knee OA
and BMD. Hip OA is estimated to have a higher heritability than
knee OA (44), with environmental risk factors such as physical
activity and BMI more strongly associated with the latter (45).
The analyses outlined here present the first comprehensive
evaluation of genetic overlap between BMD and radiographic
OA. Our results lend further support to the hypothesis of com-
mon genetic factors underlying these two traits, and establish
SMAD3 as a genome-wide significant risk locus for OA with a
potential pleiotropic effect on BMD.
Our work exemplifies the potential to uncover new disease
risk loci by combining data of epidemiologically linked traits.
Recent efforts in the development of statistical methods to de-
tect pleiotropy, as well as the establishment of cross-disorder
working groups (46) and of biobank collections (47), have made
it possible to systematically assess pleiotropy in human disease
Figure 2. Regional association plot of SMAD3. The -log(p-values) of SNPs in the
arcOGEN combined osteoarthritis (OA) data (top) and GEFOS lumbar spine bone
mineral density (LSBMD) data (bottom) are plotted against their chromosomal
position. The meta-analysis p-value of rs12901071 is plotted as a golden dia-
mond. Protein coding genes are represented by green bars.
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genetics. Methods combining univariate summary statistics of
different traits – such as the colocalisation analysis employed
here (48) – often do not require a locus to be genome-wide sig-
nificantly associated with any of the individual studies to detect
a cross-phenotype association. Hence, they can increase power
to identify associated variants or regions without the need to
collect larger sample sizes (49).
There is a stark difference in sample size and, consequently,
statistical power between the arcOGEN and GEFOS GWAS data-
sets. Larger datasets where phenotype information for both OA
and BMD is available in the same individuals will be necessary
to further disentangle the extent of shared genetics between
them. Pinpointing the common biological pathways of these
two complex traits will provide insight into the underlying
mechanisms of OA, facilitating the identification of novel tar-
gets or drug repurposing opportunities for its treatment.
Materials and Methods
Datasets
All analyses outlined here were conducted using summary as-
sociation statistics from the arcOGEN (6) and GEFOS consortia
(18). The arcOGEN data comprised three OA phenotypes: knee
OA, hip OA, and knee and/or hip OA (combined OA). A detailed
description of the contributing studies and phenotype defini-
tions can be found in (18). Briefly, OA case status was deter-
mined radiographically as a Kellgren-Lawrence grade score 2.
Most cases included in arcOGEN had progressed to a severe dis-
ease endpoint, as evident from the fact that 80% had undergone
total joint replacement surgery.
For the P-value-based overlap analysis as well as the gene
and pathway analysis, we excluded samples from London-based
cohorts (TwinsUK and Chingford Study) from the arcOGEN data-
sets to avoid overlap with GEFOS. After exclusion of 714 samples,
we carried out genome-wide association analyses on the
arcOGEN dataset for each of the three phenotype groups using
the “–method score” option in SNPTEST v2.5 (50). The full
arcOGEN dataset was used for all other analyses described.
The BMD data consisted of meta-analysis summary statis-
tics for FN and LSBMD (18).
For replication, we used summary statistics from two OA
GWAS: the UK Biobank (47) and the deCODE study. Details on
case definitions in UK Biobank and deCODE can be found in the
Supplementary Methods.
Sample sizes for each dataset are outlined in Supplementary
Material, Table S8.
Genome-wide correlation
We performed LD score regression analysis (51) on each pair-
wise combination between the BMD and OA datasets, using pre-
computed LD scores based on the European sample of the 1000
Genomes Project (52). We accounted for sample overlap be-
tween each pair of datasets through tetrachoric correlation of
the Z-scores of SNPs present in both studies.
Assessment of shared association signals
For each pairwise combination between the two BMD and three
OA phenotypes we assessed the extent of shared signals at dif-
ferent p-value cutoffs, following the approach described by
Elliott and colleagues (53). Briefly, we filtered both datasets to a
common set of SNPs on which p-value-informed LD pruning
was performed. To this end, SNPs were sorted based on their as-
sociation with OA, and, starting with the lowest p-value, any
SNP in LD with the index SNP (r2>0.05) was removed. The next
SNP was then considered, and so on.
The extent of shared association signals between OA and
BMD was assessed by counting the number of overlapping vari-
ants above and below ten different p-value thresholds (Pt: 0.5,
0.1, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005, 0.001, 5  105). To test for
significance of overlap, a chi-squared test on the resulting 22
contingency tables was performed at each Pt.
Empirical overlap p-values were obtained by repeating the
chi-squared test after randomly permuting the GEFOS p-values.
This was done 1,000,000 times to obtain a null distribution of
overlap p-values against which the original overlap p-value
could be compared.
Colocalisation analysis
We employed a Bayesian colocalisation method to search for
genomic regions harbouring cross-phenotype associations be-
tween OA and BMD (48). Briefly, the algorithm uses Z-scores and
standard errors from two association studies to generate poste-
rior probabilities for each of five hypotheses:
H0: the region contains no variants associated with trait 1
or trait 2
H1: the region contains one variant associated with trait 1
H2: the region contains one variant associated with trait 2
H3: the region contains one variant associated with both
trait 1 and trait 2
H4: the region contains one variant associated with trait 1
and a second variant associated with trait 2
Genomic regions were defined according to approximately
independent LD-blocks (54). Analogous to LD score regression,
we used the tetrachoric correlation of the Z-scores of SNPs pre-
sent in datasets as an estimate of sample overlap.
Gene and pathway analysis
Gene- and pathway analyses were performed on each OA and
BMD dataset using MAGMA (55). First, SNPs are assigned to
genes, which are tested for their association with the pheno-
type. Results from this step are then combined into pathway-
based association statistics.
For the gene analysis, we grouped variants into genes using
SNP locations from dbSNP version 135 and NCBI 37.3 gene defi-
nitions. We performed this step twice, once annotating SNPs to
a gene only if they fell within the gene’s transcription start and
stop site, and once including SNPs that fell within a 20 kilobase
window of the gene.
We ran two separate pathway analyses, one using the
Molecular Signatures Database canonical pathways collection
(56), comprising 1,329 manually curated gene-sets from nine
databases (Supplementary Material, Table S9), and one using
6,166 gene-sets from the Gene Ontology pathway database (57).
Significance was defined using a 5% FDR equivalent to a Q-
value of 0.05 for both the gene and pathway analyses (58).
Cross-phenotype meta-analysis
We used a multi-trait extension to meta-analysis to search for
novel associations in each pairwise combination of arcOGEN and
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GEFOS datasets (25). The method, CPASSOC, requires only sum-
mary statistics and generates two test statistics: the first, Shom,
assumes homogeneous effects across studies and is equivalent
to performing an inverse variance weighted meta-analysis if no
sample overlap between the studies exists. The second, Shet, is
more powerful if effects are heterogeneous between studies.
Both statistics require the specification of a correlation matrix
between the included studies. To calculate this, we followed the
approach by Park et al. (59), using all independent SNPs (r2 < 0.2)
present in both the OA and BMD dataset that were not associ-
ated with either trait (1.96>Z score< 1.96), and taking the
Pearson’s correlation of their Z-scores (25).
We performed an in-silico lookup in the UK Biobank hip and/
or knee OA data of top SNPs with P< 5108 in any of the
CPASSOC analyses that did not fall into known OA or BMD loci.
Replication and meta-analysis for OA
We took forward a total of 143 SNPs for in silico replication. This
set comprises the two most strongly associated variants (one for
each trait) in each region from the Bayesian colocalisation test,
as well as all variants overlapping at Pt¼0.005 in the SNP-based
overlap analyses. We used the METAL (60) software package to
perform inverse variance weighted meta-analysis of these SNPs
in relation to hip and/or knee OA using summary statistics from
the arcOGEN combined OA dataset (including London samples),
the UK Biobank (47) and the deCODE (61) study.
Functional follow-up of SMAD3
Samples were obtained and processed as in Ref. 25. Briefly, articu-
lar cartilage was obtained from 12 patients undergoing total joint
replacement for knee OA, and 9 patients for hip OA. Cartilage was
graded using the OARSI cartilage classification system (62,63).
Supplementary Material
Supplementary Material is available at HMG online.
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